Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (261-270 of 502) with videos related to

Pageof 51
Sort By:
Molecular Cancer Therapeutics|July 30, 2013
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancerRui Li, Zhongliang Hu, Shi-Yong Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung CancerSuzanne Jenkins, James C-H Yang, Suresh S Ramalingam, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2)Rathi N Pillai, Dean A Fennell, Vladimir Kovcin, et al.
Cancer|January 24, 2013
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancerTaofeek K Owonikoko, Mohammad S Hossain, Chandar Bhimani, et al.
Oncogene|February 1, 2022
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or bothGuangzhi Ma, Yunfu Deng, Luxi Qian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURAHelen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.
Journal of Geriatric Oncology|February 25, 2019
Clinical prognostic model for older patients with advanced non-small cell lung cancerApar Kishor Ganti, Xiaofei Wang, Thomas E Stinchcombe, et al.
Theranostics|August 10, 2021
Discovery of Small Molecule Bak Activator for Lung Cancer TherapyDongkyoo Park, Abu Syed Md Anisuzzaman, Andrew T Magis, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Pageof 51

Showing results (261-270 of 502) with videos related to

Sort By:
Pageof 51
Molecular Cancer Therapeutics|July 30, 2013
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancerRui Li, Zhongliang Hu, Shi-Yong Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung CancerSuzanne Jenkins, James C-H Yang, Suresh S Ramalingam, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2)Rathi N Pillai, Dean A Fennell, Vladimir Kovcin, et al.
Cancer|January 24, 2013
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancerTaofeek K Owonikoko, Mohammad S Hossain, Chandar Bhimani, et al.
Oncogene|February 1, 2022
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or bothGuangzhi Ma, Yunfu Deng, Luxi Qian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURAHelen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.
Journal of Geriatric Oncology|February 25, 2019
Clinical prognostic model for older patients with advanced non-small cell lung cancerApar Kishor Ganti, Xiaofei Wang, Thomas E Stinchcombe, et al.
Theranostics|August 10, 2021
Discovery of Small Molecule Bak Activator for Lung Cancer TherapyDongkyoo Park, Abu Syed Md Anisuzzaman, Andrew T Magis, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Pageof 51